Humanized CD3 Antibody VH Mutations for Balanced T-Cell Engagement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD3 antibodies, particularly bispecific antibodies, face challenges with immunogenicity and adverse effects due to high affinity to CD3, leading to cytokine storms and limited efficacy, while low affinity antibodies struggle with inefficient T cell targeting and biodistribution.
Innovation Solution
Development of humanized CD3 antibodies with optimized affinity, specifically through mutations in the VH region, such as H101G, to reduce binding affinity to CD3 without compromising cytolytic activity, allowing for tailored efficacy in targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high affinity antibodies to CD3 are used, then T cell targeting is improved, but cytokine storm and immunogenicity increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the affinity of the CD3-binding arm across multiple embodiments (Kd values from 10^-9 to 10^-11 M). This allows optimization of the balance between T cell targeting efficacy and reduction of harmful cytokine storm effects, demonstrating that intermediate affinity values can achieve both goals simultaneously.
Solution Approach 2:
The patent employs dynamic affinity modulation through engineered CD3-binding arms with different kinetic properties. The variable affinity allows the antibody to adapt its binding behavior based on local conditions, enabling flexible T cell engagement that reduces excessive activation and cytokine release while maintaining effective targeting.
2Object-generated harmful factors
If low affinity antibodies to CD3 are used, then cytokine storm is reduced, but T cell targeting and biodistribution become inefficient
Solution Approach 1:
The patent systematically adjusts the affinity parameter of the CD3-binding arm to find the optimal range that minimizes cytokine release while maintaining adequate T cell targeting. By testing multiple affinity variants, the invention identifies that specific intermediate affinity values achieve both reduced immunogenicity and sufficient targeting efficiency.
3Reliability
If mouse/rat hybrid antibodies are used, then initial therapeutic effect is achieved, but immunogenicity prevents long-term treatment
Solution Approach 1:
The patent applies local quality by humanizing only the CD3-binding variable regions while maintaining the functional Fc region. This selective humanization reduces immunogenicity in the antigen-binding portion while preserving the necessary effector functions, allowing for sustained long-term treatment without severe immune reactions.
Solution Approach 2:
The patent creates a composite antibody structure combining human Fc regions with engineered CD3-binding variable regions. This chimeric construction integrates the low immunogenicity of human antibodies with the targeted functionality needed for therapeutic effect, enabling both initial efficacy and long-term tolerability.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.